US equities
|
INTC
$112.50
▲+0.00%
MU
$1,045.56
▲+0.00%
SNDK
$1,660.46
▲+0.00%
NVDA
$239.24
▲+0.00%
SPCX
$171.92
▲+0.00%
MRVL
$287.01
▲+0.00%
AMD
$649.42
▲+0.00%
AVGO
$375.81
▲+0.00%
INTC
$112.50
▲+0.00%
MU
$1,045.56
▲+0.00%
SNDK
$1,660.46
▲+0.00%
NVDA
$239.24
▲+0.00%
SPCX
$171.92
▲+0.00%
MRVL
$287.01
▲+0.00%
AMD
$649.42
▲+0.00%
AVGO
$375.81
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
4.280
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
April 14, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
1 Cash-Burning Stock to Target This Week and 2 We Question
April 13, 2026
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...
Via
StockStory
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
April 09, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
April 05, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Myriad Genetics Inc (NASDAQ:MYGN) Stock Surges 19.6% on Strong Q4 Earnings Beat
↗
February 23, 2026
Via
Chartmill
3 Healthcare Stocks with Open Questions
April 02, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Via
StockStory
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
March 27, 2026
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via
StockStory
Topics
Government
Stocks
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
March 17, 2026
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States
From
Myriad Genetics, Inc.
Via
GlobeNewswire
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off
March 17, 2026
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Via
StockStory
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
March 11, 2026
Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted...
Via
StockStory
Topics
Artificial Intelligence
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
March 11, 2026
Shareholders of Myriad Genetics would probably like to forget the past six months even happened. The stock dropped 31.8% and now trades at $5.24. This may ha...
Via
StockStory
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know
March 10, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha...
Via
StockStory
Topics
Artificial Intelligence
Earnings
3 Stocks Under $10 We Keep Off Our Radar
March 10, 2026
Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many ...
Via
StockStory
2 Unprofitable Stocks on Our Buy List and 1 We Brush Off
March 05, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via
StockStory
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
March 03, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5.9% in the afternoon session after the company announced the launch of...
Via
StockStory
Topics
Earnings
Economy
Stocks
Myriad Commercially Launches Precise MRD with Select Community Oncologists
March 02, 2026
Launch Represents Significant Step to Broader Commercialization
From
Myriad Genetics, Inc.
Via
GlobeNewswire
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know
February 27, 2026
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key...
Via
StockStory
Topics
Economy
Government
Stocks
Why Myriad Genetics (MYGN) Stock Is Trading Up Today
February 24, 2026
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 4.9% in the morning session after the company reported better-than-expected fourth-quarter 2025 earnings that surpassed analyst...
Via
StockStory
Topics
Government
World Trade
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
February 24, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript
↗
February 23, 2026
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript
Via
The Motley Fool
What's going on in today's after hours session
↗
February 23, 2026
Via
Chartmill
Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22%
February 23, 2026
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full...
Via
StockStory
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
February 23, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know
February 23, 2026
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...
Via
StockStory
Topics
Government
World Trade
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
February 19, 2026
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
February 16, 2026
Management will participate in three upcoming investor healthcare conferences
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3 Cash-Burning Stocks We Keep Off Our Radar
February 05, 2026
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...
Via
StockStory
Topics
Bankruptcy
1 Small-Cap Stock on Our Watchlist and 2 That Underwhelm
February 02, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...
Via
StockStory
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
January 27, 2026
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm
January 21, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...
Via
StockStory
Topics
Economy
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
